MA41150B1 - Polymères de liaison aux protons pour administration orale - Google Patents

Polymères de liaison aux protons pour administration orale

Info

Publication number
MA41150B1
MA41150B1 MA41150A MA41150A MA41150B1 MA 41150 B1 MA41150 B1 MA 41150B1 MA 41150 A MA41150 A MA 41150A MA 41150 A MA41150 A MA 41150A MA 41150 B1 MA41150 B1 MA 41150B1
Authority
MA
Morocco
Prior art keywords
proton
oral administration
binding polymers
methods
pharmaceutical compositions
Prior art date
Application number
MA41150A
Other languages
English (en)
Other versions
MA41150A (fr
Inventor
Gerrit Klaerner
Eric F Connor
Randi K Gbur
Matthew J Kade
Paul H Kierstead
Jerry M Buysse
Michael J Cope
Kalpesh N Biyani
Son H Nguyen
Scott M Tabakman
Original Assignee
Tricida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tricida Inc filed Critical Tricida Inc
Publication of MA41150A publication Critical patent/MA41150A/fr
Publication of MA41150B1 publication Critical patent/MA41150B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/02—Alkylation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F226/04—Diallylamine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F26/04—Diallylamine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F271/00—Macromolecular compounds obtained by polymerising monomers on to polymers of nitrogen-containing monomers as defined in group C08F26/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2810/00—Chemical modification of a polymer
    • C08F2810/20—Chemical modification of a polymer leading to a crosslinking, either explicitly or inherently
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
    • C08J2333/24—Homopolymers or copolymers of amides or imides
    • C08J2333/26—Homopolymers or copolymers of acrylamide or methacrylamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques et des méthodes pour le traitement d'un animal, y compris un être humain, ainsi que des méthodes de préparation de ces compositions. Lesdites compositions pharmaceutiques contiennent des polymères aminés réticulés et peuvent être utilisées, par exemple, pour traiter des maladies et d'autres affections métaboliques dans lesquelles l'élimination de protons et/ou d'ions chlorure du tractus gastro-intestinal est susceptible d'apporter des bénéfices physiologiques, comme la normalisation des concentrations sériques de bicarbonate et du ph sanguin chez un animal, y compris un être humain.
MA41150A 2014-12-10 2015-12-10 Polymères de liaison aux protons pour administration orale MA41150B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462090287P 2014-12-10 2014-12-10
PCT/US2015/065041 WO2016094685A1 (fr) 2014-12-10 2015-12-10 Polymères de liaison aux protons pour administration orale

Publications (2)

Publication Number Publication Date
MA41150A MA41150A (fr) 2017-10-18
MA41150B1 true MA41150B1 (fr) 2020-06-30

Family

ID=55080167

Family Applications (3)

Application Number Title Priority Date Filing Date
MA41150A MA41150B1 (fr) 2014-12-10 2015-12-10 Polymères de liaison aux protons pour administration orale
MA053106A MA53106A (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale
MA48486A MA48486B1 (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA053106A MA53106A (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale
MA48486A MA48486B1 (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale

Country Status (26)

Country Link
US (3) US11311571B2 (fr)
EP (3) EP3718551A1 (fr)
JP (4) JP6903576B2 (fr)
KR (2) KR20240008418A (fr)
CN (2) CN107428955B (fr)
AU (2) AU2015360413B2 (fr)
BR (2) BR112017011838B1 (fr)
CA (3) CA2969238C (fr)
CY (2) CY1122928T1 (fr)
DK (2) DK3593808T3 (fr)
ES (2) ES2857177T3 (fr)
HK (1) HK1243952A1 (fr)
HR (2) HRP20200689T1 (fr)
HU (2) HUE049057T2 (fr)
IL (3) IL252439B (fr)
LT (2) LT3229816T (fr)
MA (3) MA41150B1 (fr)
MD (2) MD3593808T2 (fr)
ME (1) ME03783B (fr)
MX (3) MX2017007497A (fr)
PL (2) PL3593808T3 (fr)
PT (2) PT3593808T (fr)
RS (2) RS61409B1 (fr)
RU (2) RU2713416C2 (fr)
SI (2) SI3229816T1 (fr)
WO (1) WO2016094685A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3287133B1 (fr) 2013-06-05 2019-04-17 Tricida Inc. Polymères liant les protons pour administration orale
JP6903576B2 (ja) 2014-12-10 2021-07-14 トリシダ・インコーポレイテッドＴｒｉｃｉｄａ， Ｉｎｃ． 経口投与用プロトン結合ポリマー
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
BR112019013364A2 (pt) 2016-12-28 2020-04-14 Fujifilm Corp emulsão de polímero contendo átomo de nitrogênio ou sal do mesmo, método de produção para o mesmo e método de produção para partículas
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
EP3698799B1 (fr) 2017-10-16 2022-01-26 FUJIFILM Corporation Agent thérapeutique contre l'hyperphosphatémie
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders
MA51628A (fr) * 2018-06-04 2021-03-17 Tricida Inc Méthode de traitement de troubles de l'équilibre acido-basique
WO2019236124A1 (fr) * 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement de troubles de l'équilibre acido-basique
EP4053179A1 (fr) 2021-03-01 2022-09-07 Tricida Inc. Compositions pharmaceutiques à base de polymères réticulés de poly(allylamine)

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01100164A (ja) * 1987-10-12 1989-04-18 Shionogi & Co Ltd スルファモイル−２−ベンゾフランカルボン酸誘導体
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US5556619A (en) * 1992-08-20 1996-09-17 The Du Pont Merck Pharmaceutical Company Crosslinked polymeric ammonium salts
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
AU703842B2 (en) 1994-10-17 1999-04-01 Robert M. Bersin Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US5753706A (en) 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
JP3952223B2 (ja) * 1997-05-28 2007-08-01 日東紡績株式会社 アリルアミン重合体
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
AU2682499A (en) 1998-02-17 1999-08-30 Dimitri R. Kioussis Anion binding polymers and the use thereof
US6485703B1 (en) 1998-07-31 2002-11-26 The Texas A&M University System Compositions and methods for analyte detection
US6271264B1 (en) 1998-12-01 2001-08-07 Geltex Pharmaceuticals, Inc. Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
GB9927088D0 (en) 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
WO2001066606A1 (fr) 2000-03-09 2001-09-13 Hisamitsu Pharmaceutical Co., Inc. Resine echangeuse d'anions reticulee ou sel de celle-ci
WO2001066607A1 (fr) 2000-03-09 2001-09-13 Hisamitsu Pharmaceutical Co., Inc. Resine echangeuse d'anions reticulee ou sel de celle-ci et adsorbant phosphoreux la contenant
AU2001241095A1 (en) 2000-03-13 2001-09-24 Hisamitsu Pharmaceutical Co. Inc. Preventives and/or remedies for hyperphosphatemia
JP2002028737A (ja) 2000-07-07 2002-01-29 Fujitsu Ltd プレス打ち抜き加工方法及びプレス打ち抜き加工装置
BR0209133A (pt) 2001-04-18 2004-06-15 Genzyme Corp Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue
EP1379258B1 (fr) 2001-04-18 2006-06-28 Genzyme Corporation Sels a faible teneur en polyallylamine
CA2478599A1 (fr) 2002-03-11 2003-09-18 Novartis Ag Sels de nateglinide
US20070135335A1 (en) 2003-02-10 2007-06-14 Autogen Research Pty Ltd. Therapeutic molecules
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7767768B2 (en) 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
CA2551528A1 (fr) 2003-12-31 2005-07-21 Genzyme Corporation Agents sequestrants des acides biliaires a base de polymeres d'amine aliphatique a revetement gastro-resistant
EP1723968A1 (fr) 2004-01-29 2006-11-22 Keio University Substance modifiant la fonction des erythrocytes
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
KR101228233B1 (ko) 2004-03-30 2013-01-31 리립사, 인크. 이온 결합 중합체 및 이의 용도
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US8399025B2 (en) 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
CA2574360A1 (fr) 2004-07-19 2006-01-26 N.V. Nutricia Preparation faisant appel a l'aspartate pour reguler la glycemie
DE102004035808A1 (de) 2004-07-21 2006-03-16 Kasch, Helmut, Dr. Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20080214440A1 (en) 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US20070293429A1 (en) 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
CA2613875C (fr) 2005-07-04 2018-09-25 Ramu Krishnan Medicament ou composes pharmaceutiques ameliores et preparation associee
HUE025264T2 (en) 2005-08-18 2016-02-29 Panion & Bf Biotech Inc Pharmaceutical grade ferrite citrate for medical use
CA2620406A1 (fr) 2005-09-02 2007-03-08 Genzyme Corporation Recepteurs moleculaires polymeriques utilises comme sequestrants du phosphate
WO2007038801A2 (fr) 2005-09-30 2007-04-05 Ilypsa, Inc. Compositions de liaison aux cations monovalents comprenant des particules coeur-ecorce avec des ecorces polyvinyliques reticulees et procedes pour les utiliser
AU2006294455B2 (en) 2005-09-30 2013-06-20 Relypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
DE112006002618T5 (de) 2005-09-30 2008-08-28 Ilypsa Inc., Santa Clara Verfahren und Zusammensetzungen zum selektiven Entfernen von Kaliumionen aus dem Gastrointestinaltrakt eines Säugers
EP1946763B1 (fr) 2005-11-08 2013-08-21 Ajinomoto Co., Inc. Agent facilitant le reveil apres une anesthesie
WO2007056405A2 (fr) * 2005-11-08 2007-05-18 Genzyme Corporation POLYMERES CONTENANT DU MAGNESIUM POUR l'HYPERPHOSPHATEMIE
ITMI20052461A1 (it) 2005-12-22 2007-06-23 Univ Degli Studi Milano Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive
RU2008136081A (ru) * 2006-02-14 2010-03-20 Тева Фармасьютикл Индастриес Лтд. (Il) Фармацевтические составы с алифатическими аминными полимерами и способы их производства
JP2009536246A (ja) 2006-05-05 2009-10-08 ゲンズイメ コーポレーション ホスフェート捕捉剤としてのアミン縮合重合体
JP2009542653A (ja) 2006-07-05 2009-12-03 ジェンザイム コーポレーション リン酸塩過剰血症のための鉄（ｉｉ）含有治療剤
MX2009000611A (es) 2006-07-18 2009-04-16 Genzyme Corp Dendrimeros de amina.
CA2660029A1 (fr) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions pour administration intranasale d'insuline humaine et leurs utilisations
BRPI0716066A2 (pt) 2006-09-01 2013-09-17 Genzyme Corp composiÇço farmacÊutica, mÉtodo para tratar doenÇas, polÍmero de amina, rede polimÉrica, mÉtodo para preparar um polÍmero de amina, e, composto de amina
CA2661987C (fr) 2006-09-01 2012-11-06 Usv Limited Procede de preparation d'hydrochlorure de sevelamer et formulation de celui-ci
US7964182B2 (en) 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
WO2008029949A1 (fr) 2006-09-06 2008-03-13 Sucampo Ag Procédé et composition pour favoriser la sécrétion gastro-intestinale du bicarbonate
BRPI0717545A2 (pt) 2006-09-29 2013-10-22 Gezyme Corp Composição farmacêutica, método para tratar uma doença, polímero de amida, rede de polímero, e, método para preparar um polímero de amida
JP2010513271A (ja) 2006-12-14 2010-04-30 ゲンズイメ コーポレーション アミド−アミンポリマー組成物
WO2008103368A1 (fr) 2007-02-23 2008-08-28 Genzyme Corporation Compositions de polymère amine
US20080207766A1 (en) 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
US20100196305A1 (en) 2007-03-08 2010-08-05 Dhal Pradeep K Sulfone polymer compositions
TWI445540B (zh) 2007-04-20 2014-07-21 Ajinomoto Kk 抗低體溫組成物
JP2010525061A (ja) 2007-04-27 2010-07-22 ゲンズイメ コーポレーション アミドアミンデンドリマー組成物
US8273384B2 (en) 2007-07-02 2012-09-25 Stephen Ray Wurzberger Process for the preparation of a non-corrosive base solution and methods of using same
JPWO2009008480A1 (ja) * 2007-07-11 2010-09-09 東レ株式会社 架橋ポリアリルアミン又はその酸付加塩、及びその医薬用途
EP2016947A1 (fr) 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Nouveau processus à une étape pour préparer des polymères poly(allylamine) réticulés
WO2009023544A2 (fr) 2007-08-10 2009-02-19 Ilypsa, Inc. Compositions pharmaceutiques à base de polymères échangeurs d'anions en dose
US20090125433A1 (en) * 2007-11-13 2009-05-14 Franck Rene Mikulecz Best pre-match routing (of foreign exchange orders)
US20090156647A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Method for maintaining physiological pH levels during intensive physical exercise
EP2217215A1 (fr) 2007-12-14 2010-08-18 Genzyme Corporation Compositions pharmaceutiques enrobées
PA8807201A1 (es) 2007-12-14 2009-07-23 Genzyme Corp Composiciones farmaceuticas
JP2009179724A (ja) * 2008-01-31 2009-08-13 Toray Ind Inc 架橋ポリビニルアミン又はその酸付加塩、及びその医薬用途
WO2009097127A1 (fr) 2008-01-31 2009-08-06 Genzyme Corporation Compositions pharmaceutiques
CN102307578B (zh) 2008-03-11 2016-05-04 利维昂尼克斯公司 治疗炎症和炎症相关疾病的方法和组合物
AU2009235024A1 (en) * 2008-04-08 2009-10-15 Usv Limited Process for preparation of amine polymer salt
US20110112445A1 (en) 2008-04-11 2011-05-12 GP Investmenti S.r.l Handpiece for Ultrasound Treatments of Human Tissue
US20110142952A1 (en) 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
DE102008030046A1 (de) 2008-06-25 2009-12-31 Ratiopharm Gmbh Kompaktiertes Polyallylamin-Polymer
US20100008988A1 (en) 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010022380A2 (fr) 2008-08-22 2010-02-25 Relypsa, Inc. Compositions de polyfluoroacrylate stabilisé par polyol linéaire
US20100104527A1 (en) 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
EP3378310B1 (fr) 2008-09-25 2021-08-04 Vive Crop Protection Inc. Méthodes de production de nanoparticules polymères et formulations d'ingrédients actifs
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
WO2010059384A1 (fr) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Procédé de préparation de dérivés de pyridine tri-substituée et de pyrimidine tri-substituée utiles comme agonistes du récepteur du peptide insulinotrope glucose-dépendant
US20100166861A1 (en) 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
WO2010086881A2 (fr) 2009-01-22 2010-08-05 Usv Limited Compositions pharmaceutiques comprenant un polymère liant le phosphate
EP2488172A4 (fr) 2009-10-13 2014-08-13 Univ Michigan Compositions de dendrimères et procédés de synthèse
EP2490675B1 (fr) 2009-10-22 2019-01-23 Synthon B.V. Composition pharmaceutique comprenant sevelamer
EP2509992B1 (fr) 2009-12-07 2015-10-14 Ironwood Pharmaceuticals, Inc. Traitement des troubles gastro-intestinaux
BR112012021448A2 (pt) 2010-02-24 2016-05-31 Relypsa Inc polímero de amina, método para tratar doença, método de remoção de sais biliares de um indivíduo animal, método para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina.
JP5865847B2 (ja) 2010-02-24 2016-02-17 レリプサ， インコーポレイテッド 胆汁酸捕捉剤として使用するための架橋されたポリビニルアミン、ポリアリルアミンおよびポリエチレンイミン
IT1406068B1 (it) 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR101238210B1 (ko) 2011-06-30 2013-03-04 엘지전자 주식회사 이동 단말기
US20130137772A1 (en) 2011-11-29 2013-05-30 Raymond J. Bergeron Hydroxypolyamine salts
AU2013278000A1 (en) 2012-06-21 2015-01-22 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients
BR112015007749A2 (pt) 2012-10-08 2017-07-04 Relypsa Inc métodos para tratamento de hipertensão , de hipercaliemia , e de doença renal crônica.
EP3287133B1 (fr) 2013-06-05 2019-04-17 Tricida Inc. Polymères liant les protons pour administration orale
EP3747432A1 (fr) 2013-11-04 2020-12-09 Keryx Biopharmaceuticals, Inc. Citrate ferrique pour réduire l'insuffisance cardiaque chez des patients souffrant d'une maladie rénale chronique
JP6903576B2 (ja) 2014-12-10 2021-07-14 トリシダ・インコーポレイテッドＴｒｉｃｉｄａ， Ｉｎｃ． 経口投与用プロトン結合ポリマー
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders
SG11202003453QA (en) 2017-11-03 2020-05-28 Tricida Inc Method of treating acid-base disorders
WO2019236639A1 (fr) 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement des troubles de l'équilibre acido-basique
WO2019236124A1 (fr) 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement de troubles de l'équilibre acido-basique
MA51628A (fr) 2018-06-04 2021-03-17 Tricida Inc Méthode de traitement de troubles de l'équilibre acido-basique
US20200306209A1 (en) 2019-03-27 2020-10-01 Tricida, Inc. Method of treating acid-base disorders

Also Published As

Publication number Publication date
CA2969238C (fr) 2023-10-17
JP2020158530A (ja) 2020-10-01
PL3593808T3 (pl) 2021-06-14
MA48486A (fr) 2020-01-15
US20180021370A1 (en) 2018-01-25
ES2857177T3 (es) 2021-09-28
EP3229816B1 (fr) 2020-02-05
LT3229816T (lt) 2020-05-25
IL278034A (en) 2020-11-30
CN107428955B (zh) 2021-09-21
RU2017124157A (ru) 2019-01-10
MX2021004558A (es) 2022-05-03
RS61409B1 (sr) 2021-03-31
BR112017011838A2 (pt) 2017-12-26
MA48486B1 (fr) 2021-03-31
CN107428955A (zh) 2017-12-01
JP2017538822A (ja) 2017-12-28
MD3229816T2 (ro) 2020-07-31
IL252439A0 (en) 2017-07-31
HRP20210204T1 (hr) 2021-03-19
JP2021176971A (ja) 2021-11-11
JP6921276B2 (ja) 2021-08-18
ES2787218T3 (es) 2020-10-15
RU2017124157A3 (fr) 2019-07-17
SI3229816T1 (sl) 2020-09-30
JP6903576B2 (ja) 2021-07-14
CN113855703A (zh) 2021-12-31
JP7258087B2 (ja) 2023-04-14
HUE049057T2 (hu) 2020-08-28
IL252439B (en) 2020-10-29
EP3718551A1 (fr) 2020-10-07
AU2015360413B2 (en) 2021-07-08
MD3593808T2 (ro) 2021-05-31
HUE052736T2 (hu) 2021-05-28
RS60208B1 (sr) 2020-06-30
MX2017007497A (es) 2017-10-04
PT3593808T (pt) 2021-02-11
US20220339186A1 (en) 2022-10-27
LT3593808T (lt) 2021-02-25
KR20170095269A (ko) 2017-08-22
IL278034B (en) 2022-04-01
KR102625115B1 (ko) 2024-01-12
SI3593808T1 (sl) 2021-03-31
JP2023085428A (ja) 2023-06-20
PL3229816T3 (pl) 2020-09-21
PT3229816T (pt) 2020-05-11
CY1122928T1 (el) 2021-10-29
EP3593808A1 (fr) 2020-01-15
CY1124073T1 (el) 2022-05-27
US11738041B2 (en) 2023-08-29
DK3593808T3 (da) 2021-02-01
US11311571B2 (en) 2022-04-26
MX2019014711A (es) 2020-02-12
CA2969238A1 (fr) 2016-06-16
KR20240008418A (ko) 2024-01-18
HRP20200689T1 (hr) 2020-07-24
RU2020102937A (ru) 2020-02-13
HK1243952A1 (zh) 2018-07-27
ME03783B (fr) 2021-04-20
AU2021245144A1 (en) 2021-11-04
IL290729A (en) 2022-04-01
US20230405043A1 (en) 2023-12-21
WO2016094685A1 (fr) 2016-06-16
BR112017011838B1 (pt) 2023-04-25
EP3229816A1 (fr) 2017-10-18
MA41150A (fr) 2017-10-18
DK3229816T3 (en) 2020-04-27
BR122021001914B1 (pt) 2024-02-27
MA53106A (fr) 2021-09-15
RU2713416C2 (ru) 2020-02-05
EP3593808B1 (fr) 2020-12-09
AU2015360413A1 (en) 2017-06-08
AU2021245144B2 (en) 2024-01-11
CA3205149A1 (fr) 2016-06-16
CA3164664A1 (fr) 2016-06-16

Similar Documents

Publication Publication Date Title
MA41150B1 (fr) Polymères de liaison aux protons pour administration orale
MY197091A (en) Compositions for treating acid-base disorders
MX2021013880A (es) Polimeros enlazados al proton para administracion oral.
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
MY173699A (en) Novel compounds for the treatment of diseases associated with amyloid of amyloid-like proteins
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
FI3347002T3 (fi) Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa
EA200802398A1 (ru) Гранулы липоевой кислоты
EA201170117A1 (ru) Противоаллергические биополимеры морского происхождения
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
BR102016012501A2 (pt) peptídeo, composição farmacêutica, uso do peptídeo, e, uso da composição farmacêutica
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
RU2353358C2 (ru) Производные прегабалина для лечения приливов
UA111587C2 (uk) Сполуки для лікування захворювань, пов'язаних з амілоїдними або амілоїдоподібними білками
PH12020551900A1 (en) Novel compound exhibiting enteropeptidase inhibitory activity
RU2018110031A (ru) Способ лечения и профилактика гриппа
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
UA102651U (uk) Спосіб корекції ферментної системи антиоксидантного захисту організму глибокотільних корів за ендотоксикозу